MDMA study for people with moderate liver problems
Part of Digestive system clinical trials.
This Phase 1 study tests how MDMA behaves and is tolerated in people with moderate liver impairment compared with people whose livers work normally. It may help doctors understand dosing and safety for people with liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 65 and weigh over 45 kg
- You either have moderate liver impairment (Child-Pugh class B) or normal liver function
- You must be able to understand the study and sign informed consent
- Breath alcohol test must be negative right before dosing, and urine drug test must be negative at screening and before dosing
- Carbohydrate-deficient transferrin blood test must be negative at screening
- You must not have certain mental health conditions, pregnancy/nursing, or inability to stay in the clinic for the required time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how the body processes and tolerates a new experimental drug (MDR-001) in people with mild to moderate liver disease. The research helps doctors understand if the drug is safe and how it works when liver function is reduced.
This early-phase study looks at whether MDMA is tolerable (safe enough) in people diagnosed with schizophrenia. Researchers will check safety while you stay stable on your usual care.
This trial tests how the body processes ammoxetine in people with mild or moderate liver impairment compared to people with normal liver function. It aims to find out if the drug is safe and how it works in these groups.
This trial tests if MDMA-assisted therapy can help mental healthcare providers. It involves taking MDMA in a therapeutic setting while being recorded, and you must be trained in this type of therapy.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.